Dopamine in Acute Decompensated Heart Failure II

• Status: Terminated
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to compare the effects of 1) high-dose furosemide, 2) low-dose furosemide, and 3) low-dose furosemide combined with low-dose dopamine on diuresis, clinical status, renal function, electrolyte balance, length of stay, and 60-day post-discharge outcomes in patients hospitalized with acute decompensated heart failure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Larissa University Hospital
• Treatments: Dopamine; Dopamine Agents; Furosemide

Criteria

Inclusion Criteria:

• patients with New York Heart Association (NYHA) functional class IV heart failure according to the American Heart Association (AHA) classification, namely dyspnea on minimal exertion or rest dyspnea, orthopnea, and paroxysmal nocturnal dyspnea,

• signs of congestion (third heart sound or pulmonary rales on physical examination),

• pulmonary congestion on chest x-ray,

• serum B-type natriuretic peptide levels > 400 pg/ml or NT-proBNP > 1500 pg/ml,

• echocardiographic documentation of systolic or diastolic dysfunction,

• age >18 years old,

• on medical therapy with an ACE-inhibitor and/or a β-blocker,

• experiencing an acute decompensation of known chronic HF,

• baseline oxygen saturation <90% on admission arterial blood gas

Exclusion Criteria:

• acute de novo HF;

• severe renal failure (serum creatinine >200 μmol/L or GFR <30 ml/min/1.73m2)

• admission systolic blood pressure <90 mm Hg;

• severe valvular disease;

• known adverse reactions to furosemide or dopamine;

• HF secondary to congenital heart disease;

• a scheduled procedure with a need for IV contrast dye;

• a scheduled cardiac surgery within 6 months